OSE Immunotherapeutics Presents Promising New Data on OSE-127’s Potential to Treat IBD

OSE Immunotherapeutics Presents Promising New Data on OSE-127’s Potential to Treat IBD
OSE Immunotherapeutics presented new preclinical results on its investigational therapy candidate OSE-127, further validating its potential for the treatment of inflammatory bowel diseases (IBD). Results were presented in an abstract titled, “Interleukin-7 receptor pathway controls human T cell homing to the gut and predicts response to anti-TNFα therapy in IBD,” at the recent annual congress of the

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *